Skip to content

Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study

Will Long-term Endogenous Androgen Priming, Using a Combination of Low Dose HCG and Aromatase Inhibitor in Bologna Criteria Poor Responder Patients Increase Ovarian Reserve Parameters - A Pilot Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03447184
Enrollment
30
Registered
2018-02-27
Start date
2018-03-26
Completion date
2019-03-01
Last updated
2019-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poor Ovarian Response

Brief summary

Until now no scientific clinical evidence exists regarding the possible impact of long term endogenous androgen priming in IVF patients aligned with the Bologna Criteria, in specific the impact of priming on serum parameters correlated with the ovarian reserve, antral follicle count, and the number of retrievable follicles. Thus, this pilot-study will explore a new suggested protocol for the Bologna criteria patient developed from basic physiology, and will if successful result in a subsequent randomized controlled trial in the same subset of patients, enabling a possible paradigm shift in the treatment of poor ovarian response (POR).

Detailed description

A single center study pilot study in 30 IVF Bologna criteria POR patients. All patients fulfilling the ESHRE Bologna criteria will be eligible for inclusion. Eight weeks prior to stimulation for IVF, patients will start treatment with a low dose of rhCG (Ovitrelle). At the same time daily treatment with the aromatase inhibitor daily will commence, concomitantly with GnRHa down-regulation with a depot GnRHa. After 8 weeks, stimulation will be performed with a fixed dose of 300 IU rFSH (Gonal F, Merck) for the first 5 days in patients ≤ 34 years of age and 300 IU Pergoveris (Merck) in patients ≥ 35 years of age. The use of hCG and aromatase inhibitor will stop on the first day of stimulation. Monitoring will be performed according to the standard procedure of the clinic. Patients will receive a bolus of 6.500 IU rhCG (Ovitrelle, Merck) for triggering of final oocyte maturation. Oocyte pick-up and embryo transfer will be performed according to the policy of the clinic. Oocyte pick-up (OPU) and embryo transfer will be performed according to standard procedures.

Interventions

DRUGAndrogen priming

Androgen priming: with a low dose of recombinant hCG, aromatase inhibitor, and a depot GnRHa for 8 weeks Stimulation: a standard rFSH stimulation with either 300 IU rFSH or 300 IU (rFSH + rLH) Blood sampling: 6 blood samples to measure FSH, LH, E2, testosterone, and AMH Ultrasound examination: to count all antral follicles, 2-10 mm in each ovary Follicular fluid: to analyze E2, androstenedione, testosterone, progesterone, inhibin B. Granulosa cells: to analyze gene expression in cumulus and mural granulosa cells of Luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD), inhibin-Ba (INHB-A) receptor, androgen and FSH receptor

Sponsors

Mỹ Đức Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 41 Years
Healthy volunteers
No

Inclusion criteria

* Age 18 - 41 years * BMI \< 30 kg/m2 * Ovarian reserve, according to the ESHRE Bologna Criteria measured within two months prior to stimulation start Bologna criteria: At least two of the following three features present: * Advanced maternal age (≥40 years) or any other risk factor for POR * A previous POR (≤3 oocytes with a conventional stimulation protocol) * An abnormal ovarian reserve test (i.e. antral follicle count \< 5-7 follicles or AMH\< 0.5 - 1.1 ng/mL) * Poor responder if - Two previous episodes of POR after maximal stimulation (300 IU) * Receiving GnRH-antagonist co-treatment during ovarian stimulation * Agreement to participate in the study, and to disclose any medical events to the investigator. The subject must be willing and able to comply with the protocol requirements for the duration of the study. * Have given written informed consent with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.

Exclusion criteria

* Chronical medical conditions like Diabetes, Crohns disease, Thyroid disease, Hepatitis B and Sexually Transmitted Diseases Simultaneous participation in an interventional clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Serum concentrations of AMH8 weeks after starting androgen primingBlood sampling

Secondary

MeasureTime frameDescription
Number of antral follicles8 weeks after starting androgen primingFollicles 2-10mm on ultrasound
Serum concentrations of testosteroneUp to 2 weeks after starting FSH stimulationBlood sampling
Serum concentrations of hCGUp to 2 weeks after starting FSH stimulationBlood sampling
Serum concentrations of progesteroneUp to 2 weeks after starting FSH stimulationBlood sampling
Number of pre-ovulatory folliclesUp to 2 weeks after starting FSH stimulationFollicles \>/= 14 mm on ultrasound

Other

MeasureTime frameDescription
Cumulus and mural 3β-hydroxy-steroid-dehydrogenase (3ßHSD) gene expressionUp to one hour after ovum pick-upCumulus and mural granulosa cells from oocyte from the first follicle in each women were isolated immediately after ovum pick-up and snap frozen for analysis of 3ßHSD gene expression. qPCR was performed and calculation of the expression level of the gene of interest was carried out according to the comparative method, normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for relative quantification of gene expression.
Cumulus and mural inhibin-Ba (INHB-A) receptor gene expressionUp to one hour after ovum pick-upCumulus and mural granulosa cells from oocyte from the first follicle in each women were isolated immediately after ovum pick-up and snap frozen for analysis of INHB-A gene expression. qPCR was performed and calculation of the expression level of the gene of interest was carried out according to the comparative method, normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for relative quantification of gene expression.
Follicular fluid concentration of estradiolUp to one hour after ovum pick-upAspiration of follicular fluid while doing ovum pick-up
Cumulus and mural FSH receptor gene expressionUp to one hour after ovum pick-upCumulus and mural granulosa cells from oocyte from the first follicle in each women were isolated immediately after ovum pick-up and snap frozen for analysis of FSH receptor gene expression. qPCR was performed and calculation of the expression level of the gene of interest was carried out according to the comparative method, normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for relative quantification of gene expression.
Cumulus and mural androgen receptor gene expressionUp to one hour after ovum pick-upCumulus and mural granulosa cells from oocyte from the first follicle in each women were isolated immediately after ovum pick-up and snap frozen for analysis of androgen receptor gene expression. qPCR was performed and calculation of the expression level of the gene of interest was carried out according to the comparative method, normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for relative quantification of gene expression.
Follicular fluid concentration of androstenedioneUp to one hour after ovum pick-upAspiration of follicular fluid while doing ovum pick-up
Follicular fluid concentration of testosteroneUp to one hour after ovum pick-upAspiration of follicular fluid while doing ovum pick-up
Follicular fluid concentration of progesteroneUp to one hour after ovum pick-upAspiration of follicular fluid while doing ovum pick-up
Follicular fluid concentration of inhibin BUp to one hour after ovum pick-upAspiration of follicular fluid while doing ovum pick-up
Cumulus and mural Luteinising hormone receptor (LHR) gene expressionUp to one hour after ovum pick-upCumulus and mural granulosa cells from oocyte from the first follicle in each women were isolated immediately after ovum pick-up and snap frozen for analysis of LHR gene expression. qPCR was performed and calculation of the expression level of the gene of interest was carried out according to the comparative method, normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for relative quantification of gene expression.

Countries

Vietnam

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026